A novel image-based high-throughput screening assay discovers therapeutic candidates for adult polyglucosan body disease.

Glycogen storage disorders (GSDs) are caused by excessive accumulation of glycogen. Some GSDs [adult polyglucosan (PG) body disease (APBD), and Tarui and Lafora diseases] are caused by intracellular accumulation of insoluble inclusions, called PG bodies (PBs), which are chiefly composed of malconstructed glycogen. We developed an APBD patient skin fibroblast cell-based assay for PB identification, where the bodies are identified as amylase-resistant periodic acid-Schiff's-stained structures, and quantified. We screened the DIVERSet CL 10 084 compound library using this assay in high-throughput format and discovered 11 dose-dependent and 8 non-dose-dependent PB-reducing hits. Approximately 70% of the hits appear to act through reducing glycogen synthase (GS) activity, which can elongate glycogen chains and presumably promote PB generation. Some of these GS inhibiting hits were also computationally predicted to be similar to drugs interacting with the GS activator protein phosphatase 1. Our work paves the way to discovering medications for the treatment of PB-involving GSD, which are extremely severe or fatal disorders.

[1]  Dan Peer.  Handbook of Harnessing Biomaterials in Nanomedicine : Preparation, Toxicity, and Applications , 2012 .

[2]  Adam Yasgar,et al.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[3]  H. Stukenbrok,et al.  STUDIES IN MYOCLONUS EPILEPSY III. THE EFFECTS OF AMYLOLYTIC ENZYMES ON THE ULTRASTRUCTURE OF LAFORA BODIES , 1971, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[4]  C. Ackerley,et al.  Inhibiting glycogen synthesis prevents lafora disease in a mouse model , 2013, Annals of neurology.

[5]  Michael H. Shuman,et al.  Assessing cellular toxicities in fibroblasts upon exposure to lipid-based nanoparticles: a high content analysis approach , 2011, Nanotechnology.

[6]  C. Klein,et al.  A 63-year-old woman with urinary incontinence and progressive gait disorder , 2009, Neurology.

[7]  S. Dimauro,et al.  Late‐onset muscle phosphofructokinase deficiency , 1988, Neurology.

[8]  A. Gold.  Kinetic mechanism of rabbit muscle glycogen synthase I. , 1980, Biochemistry.

[9]  S. Dimauro,et al.  Polyglucosan neurotoxicity caused by glycogen branching enzyme deficiency can be reversed by inhibition of glycogen synthase , 2013, Journal of neurochemistry.

[10]  Hotchkiss Rd,et al.  A microchemical reaction resulting in the staining of polysaccharide structures in fixed tissue preparations. , 1948 .

[11]  O. J. Trask,et al.  Assay Guidance Manual , 2004 .

[12]  Hanoch Senderowitz,et al.  A reliable computational workflow for the selection of optimal screening libraries , 2015, Journal of Cheminformatics.

[13]  Yuan-Tsong Chen,et al.  Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen-branching enzyme gene. , 1996, The Journal of clinical investigation.

[14]  H. Sølling.  Studies on the allosteric properties of glycogen synthase I. , 1979, European journal of biochemistry.

[15]  L. Kelley,et al.  An automated approach for clustering an ensemble of NMR-derived protein structures into conformationally related subfamilies. , 1996, Protein engineering.

[16]  R. Schiffmann,et al.  Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings , 2012, Annals of neurology.

[17]  Structural profiling and biological performance of phospholipid-hyaluronan functionalized single-walled carbon nanotubes. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[18]  J. Baell,et al.  Chemistry: Chemical con artists foil drug discovery , 2014, Nature.

[19]  Yang Liu,et al.  Laforin–Malin Complex Degrades Polyglucosan Bodies in Concert with Glycogen Debranching Enzyme and Brain Isoform Glycogen Phosphorylase , 2013, Molecular Neurobiology.

[20]  P. Roach.  Glycogen phosphorylation and Lafora disease. , 2015, Molecular aspects of medicine.

[21]  Roger Schibli,et al.  Can animal data predict human outcome? Problems and pitfalls of translational animal research , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  Tian Zhu,et al.  Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis. , 2013, Journal of medicinal chemistry.

[23]  Afra H. Wang,et al.  Phosphorylation prevents polyglucosan transport in Lafora disease , 2012, Neurology.

[24]  K. Klinger,et al.  Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease. , 2010, Molecular genetics and metabolism.

[25]  M. Peggie,et al.  Allosteric regulation of glycogen synthase controls glycogen synthesis in muscle. , 2010, Cell metabolism.

[26]  Nir Giladi,et al.  Frequent misdiagnosis of adult polyglucosan body disease , 2015, Journal of Neurology.

[27]  P. Darlington,et al.  Detecting glycogen in peripheral blood mononuclear cells with periodic acid schiff staining. , 2014, Journal of visualized experiments : JoVE.